While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
At a conference largely focused on big biopharma a few biotech catalysts stand out.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.